C
Charles Brenner
Researcher at City of Hope National Medical Center
Publications - 182
Citations - 13496
Charles Brenner is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: NAD+ kinase & Nicotinamide riboside. The author has an hindex of 55, co-authored 176 publications receiving 11308 citations. Previous affiliations of Charles Brenner include Queen's University Belfast & Stanford University.
Papers
More filters
Journal ArticleDOI
p53 Activation by Knockdown Technologies
Mara E. Robu,Jon D. Larson,Aidas Nasevicius,Aidas Nasevicius,Soraya Beiraghi,Charles Brenner,Steven A. Farber,Stephen C. Ekker +7 more
TL;DR: It is shown here that MO off-targeting results in induction of a p53-dependent cell death pathway, and p53 inhibition could potentially be applicable to other systems to suppress off- target effects caused by other knockdown technologies.
Journal ArticleDOI
NAD+ metabolism in health and disease.
TL;DR: Nicotinamide riboside, the recently discovered nucleoside precursor of NAD(+ in eukaryotic systems, might have advantages as a therapy to elevate NAD(+) without inhibiting sirtuins, which is associated with high-dose nicotinamide, or incurring the unpleasant side-effects of high- dose nicotinic acid.
Journal ArticleDOI
Discoveries of Nicotinamide Riboside as a Nutrient and Conserved NRK Genes Establish a Preiss-Handler Independent Route to NAD+ in Fungi and Humans
TL;DR: The accepted view of eukaryotic NAD+ biosynthesis, that all anabolism flows through nicotinic acid mononucleotide, was challenged experimentally and revealed that nicotinamide riboside is an unanticipated NAD+ precursor in yeast.
Journal ArticleDOI
Nicotinic Acid, Nicotinamide, and Nicotinamide Riboside: A Molecular Evaluation of NAD+ Precursor Vitamins in Human Nutrition
Katrina L. Bogan,Charles Brenner +1 more
TL;DR: Prospects for human nicotinamide riboside supplementation are presented and areas for future research are proposed to enhance reverse cholesterol transport and protect against neurological degeneration.
Journal ArticleDOI
Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast.
Ainslie B. Parsons,Andres Lopez,Inmar E. Givoni,David E. Williams,Christopher A. Gray,Justin Porter,Gordon Chua,Richelle Sopko,Renee L. Brost,Cheuk-Hei Ho,Jiyi Wang,Troy Ketela,Charles Brenner,Julie A. Brill,G. Esteban Fernandez,Todd C. Lorenz,Gregory S. Payne,Satoru Ishihara,Yoshikazu Ohya,Brenda J. Andrews,Timothy P. Hughes,Brendan J. Frey,Todd R. Graham,Raymond J. Andersen,Charles Boone +24 more
TL;DR: A compendium of "chemical-genetic interaction" profiles by testing the collection of viable yeast haploid deletion mutants for hypersensitivity to 82 compounds and natural product extracts is generated, found to disrupt calcium homeostasis and phosphatidylserine was recognized as a target for papuamide B, a cytotoxic lipopeptide with anti-HIV activity.